{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Krystal Biotech pushes three trial milestones into 2027","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://s.yimg.com/lo/mysterio/api/485216693cfdc091eb1623967b2b22cf8f23affbcd02868f35bb034fcf8b7e0d/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Ftikr_258%2Fdebe9eee083f8056aa9718d782dcb827","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/XMWNdB5ADVwQXXQV1f6Hiv\" style=\"color:#fff;text-decoration:none;\">Krystal Biotech pushes three trial milestones into 2027</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Krystal Biotech pushed milestones for three treatment trials into 2027 in its Nov. 2 report, despite a 30% increase in third-quarter sales of its gene therapy Vyjuvek to $127.3 million.</p>\n    </blockquote>"}